AB Science: new strategy and capital increase
The company intends to focus its development strategy on amyotrophic lateral sclerosis with its masitinib platform, on the second microtubule platform and to seek partnerships for non-rare disease indications for masitinib.
The capital increase gives rise to the issue of 2,608,686 shares at a price of 5.75 euros, with warrants attached, the exercise of which would bring the total amount of the operation to around 26.3 million euros (i.e. a total of 3,913,029 new shares).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction